Genefron

Company Overview

Snapshot

Founded in January 2011 by Yaniv Kotler, Genefron operates with 1–10 employees. The company holds one patent and has developed diagnostic kits for viral and autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and cytomegalovirus, which are CE marked and Israeli OTC.

Business overview

Genefron specializes in developing and producing personalized genomic diagnostic kits. The company leverages gene expression signatures derived from bioinformatic developments to provide in-vitro companion diagnostics. Its core technology focuses on genetics and biomarkers, serving markets in Israel, particularly targeting laboratories, chronic patients, and women within the broader healthcare and life sciences sectors.

Company Intelligence Q&A

What is Genefron's primary focus?

Genefron develops and produces genome-based personalized diagnostic kits, utilizing gene expression signatures from bioinformatic developments to offer in-vitro companion diagnostics.

When was Genefron founded and by whom?

Genefron was founded in January 2011 by Yaniv Kotler.

What products has Genefron developed?

Genefron has developed diagnostic kits for viral and autoimmune diseases and therapies, including IFR 300 In RA, IFR 100 In MS, and IFR 200, which are CE marked and Israeli OTC.

In which sector does Genefron primarily operate?

Genefron operates primarily in the Health Tech & Life Sciences sector, specifically focusing on Digital Medical Diagnostics and Medical Decision Support.

What is the current status of Genefron?

Genefron is currently Non Active, having ceased to operate in August 2024.